StreetInsider.com News Articles

Form 4 Alkermes plc. For: Aug 03 Filed by: snyderman nancy lynn MD

Mon, 03 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260803/26859784.html

Form 4 Alkermes plc. For: Aug 03 Filed by: snyderman nancy lynn MD

Mon, 03 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260803/26859784.html

Form 4 Alkermes plc. For: Aug 03 Filed by: Hopkinson Craig C.

Mon, 03 Aug 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26859778.html

Form 4 Alkermes plc. For: Aug 03 Filed by: Hopkinson Craig C.

Mon, 03 Aug 2026 19:13:00 -0400

si-local-file:///var/storage/secattach/20260803/26859778.html

Form 4 Alkermes plc. For: Aug 03 Filed by: Gaffin David Joseph

Mon, 03 Aug 2026 19:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26859773.html

Form 4 Alkermes plc. For: Aug 03 Filed by: Gaffin David Joseph

Mon, 03 Aug 2026 19:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26859773.html

Form 144 Alkermes plc. Filed by: snyderman nancy lynn MD

Mon, 03 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260803/26858602.html

Form 144 Alkermes plc. Filed by: snyderman nancy lynn MD

Mon, 03 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260803/26858602.html

Form 144 Alkermes plc. Filed by: Gaffin David Joseph

Mon, 03 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260803/26858567.html

Form 144 Alkermes plc. Filed by: Gaffin David Joseph

Mon, 03 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260803/26858567.html

Form 144 Alkermes plc. Filed by: Hopkinson Craig C.

Mon, 03 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260803/26858544.html

Form 144 Alkermes plc. Filed by: Hopkinson Craig C.

Mon, 03 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260803/26858544.html

Form 8-K/A Alkermes plc. For: Feb 24

Mon, 03 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26857862.html

Form 8-K/A Alkermes plc. For: Feb 24

Mon, 03 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260803/26857862.html

Weakness in this biotech stock is a buying opportunity: Mizuho

Fri, 31 Jul 2026 09:00:00 -0400

Mizuho reiterated an Outperform rating and $65 price target on a key biotech stock in a note on Friday, telling investors that a selloff following the drugmaker's second-quarter results is a buying opportunity.

Analyst Uy Ear said Alkermes (NASDAQ: ALKS) posted a solid quarter, with product sales, manufacturing and royalty revenues broadly in line with estimates and consensus after stripping out several one-time items.

Mizuho believes the day's weakness "could be driven by algorithmic selling" following a GAAP net income reduction tied to a roughly $25 million change in contingent consideration fair value. Importantly, the firm noted, Alkermes maintained its full-year

Weakness in this biotech stock is a buying opportunity: Mizuho

Fri, 31 Jul 2026 09:00:00 -0400

H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)

Thu, 30 Jul 2026 06:51:15 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating on Alkermes (NASDAQ: ALKS).

The analyst commented: "Proprietary product sales increased 34% y/y to $411.7M, clear of consensus at $397M. However, 2Q's results benefited from $15M of revenue benefited from favorable gross-to-net dynamics and inventory timing, so performance was largely consistent with expectations from an end-demand standpoint. Consistent with that, the company largely reiterated guidance for the year. We saw modest upside from Vivitrol ($124.5M vs. Street at $119M) and Aristada family ($96.7M vs. Street at $96M), countered by a modest miss by Lybalvi ($94.0M vs Street at $97M). That said, Lybalvi

Alkermes (ALKS) PT Raised to $61 at JPMorgan

Wed, 29 Jul 2026 08:28:00 -0400

JPMorgan analyst Jessica Fye raised the price target on Alkermes (NASDAQ: ALKS) to $61.00 (from $60.00) while maintaining a Neutral rating.

Alkermes (ALKS) PT Raised to $58 at Baird

Wed, 29 Jul 2026 06:38:03 -0400

Baird analyst Joel Beatty raised the price target on Alkermes (NASDAQ: ALKS) to $58.00 (from $48.00) while maintaining a Outperform rating.

Form S-8 Alkermes plc.

Tue, 28 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260728/26828128.html

Form S-8 Alkermes plc.

Tue, 28 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260728/26828128.html

Form 10-Q Alkermes plc. For: Jun 30

Tue, 28 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260728/26823748.html

Form 10-Q Alkermes plc. For: Jun 30

Tue, 28 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260728/26823748.html

Alkermes (ALKS) PT Raised to $65 at Piper Sandler

Tue, 28 Jul 2026 08:22:26 -0400

(Updated - July 28, 2026 8:22 AM EDT)

Piper Sandler analyst David Amsellem raised the price target on Alkermes (NASDAQ: ALKS) to $65.00 (from $43.00) while maintaining an Overweight rating.

The analyst commented: "Making A Case For Further Value Creation; With Alkermes shares up ~88% year-to-date and up ~76% since Lilly (LLY; not covered) announced plans to acquire Centessa, it would be tempting to ponder if ALKS is indeed fully valued at an EV of ~$9.7B. We would argue that it is not. More to the point, though LLY’s purchase of Centessa underscored the multi-indication potential of the orexin 2 receptor (OX2R)

Alkermes (ALKS) PT Raised to $65 at Piper Sandler

Tue, 28 Jul 2026 08:22:26 -0400

(Updated - July 28, 2026 8:22 AM EDT)

Piper Sandler analyst David Amsellem raised the price target on Alkermes (NASDAQ: ALKS) to $65.00 (from $43.00) while maintaining an Overweight rating.